Related Experiment Video
Updated: Jul 30, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.2K
Chemoradiotherapy for Small-Cell Prostate Carcinoma: A Case Report.
Kenji Makita1,2,3, Yasushi Hamamoto1, Kei Nagasaki1
1Department of Radiation Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, JPN.
Cureus
|May 11, 2023
Summary
Small-cell prostate carcinoma (SCPC) is rare. Despite a complete response to chemoradiotherapy, local recurrence occurred, highlighting the need for optimized radiotherapy strategies for better local control in SCPC patients.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Imaging
Background:
- Small-cell prostate carcinoma (SCPC) is a rare and aggressive malignancy.
- Standard treatment protocols for SCPC are not well-established due to its rarity.
- Multimodal therapy involving chemoradiotherapy is a treatment approach for SCPC.
Observation:
- A 60-year-old male diagnosed with SCPC underwent external-beam radiotherapy (60 Gy in 30 fractions) combined with six cycles of cisplatin (CDDP) and etoposide (VP-16) chemotherapy.
- Post-treatment fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) indicated a complete response to the chemoradiotherapy.
- Local tumor recurrence was detected within the original tumor volume 12 months after completing treatment.
Findings:
- Despite achieving a complete response on FDG-PET/CT, local recurrence of SCPC occurred 12 months post-chemoradiotherapy.
- The recurrence happened within the gross tumor volume, suggesting limitations in achieving durable local control with the current regimen.
- This case underscores the challenges in managing rare SCPC, even with standard chemotherapy and radiotherapy doses.
Implications:
- Radiotherapy plays a crucial role in the local control of SCPC.
- Further research is essential to determine optimal radiotherapy doses and target volumes for SCPC.
- Investigating novel radiotherapy techniques and fractionation schedules may improve outcomes for patients with this rare cancer.
